Calidi Biotherapeutics Inc - Ordinary Shares - Class A
CLDI
Get informed when a big investor buys or sells
+ FollowMarket Cap$616.99K
Close$
$0.71
48.9% downside
Current Fair Value
48.9% downsideOvervalued by 48.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $616,986.00 |
|---|---|
| Enterprise Value | $-2,112,014.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-95.2 |
| Beta | 1.33 |
| Outstanding Shares | 1,416,000 |
Return
| Return on Equity | -748.64% |
|---|---|
| Return on Assets | -325.58% |
| Return on Invested Capital | -459.99% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.69 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.64 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.49%▲ 13.28% |
|---|---|
| Total Invested | $479,037▼ 8.70% |
| Investors Holding | 29▲ 2.00% |
ESG Score
No data